Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Labat AfricaJSE:LAB 3-Year Revenue Growth Rate is 34.20% as of Nov. 2025. The stock has 8 warning signs investors should review. Among 904 Drug Manufacturers companies, Labat Africa ranks better than 92.59% on this metric.
During the past 12 months, Labat Africa's average Revenue per Share Growth Rate was 227.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 34.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -3.90% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 5.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Labat Africa was 78.20% per year. The lowest was -55.20% per year. And the median was -14.30% per year.
Labat Africa (JSE:LAB) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Labat Africa 3-Year Revenue Growth Rate Related Terms
JSE:LAB vs ZTS, UTHR, VTRS: 3-Year Revenue Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa 3-Year Revenue Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Labat Africa's 3-Year Revenue Growth Rate falls into.
Labat Africa 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of 34.20% mean?
Labat Africa (JSE:LAB) has a 3-Year Revenue Growth Rate of 34.20% as of Nov. 2025. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Labat Africa and its competitors. According to the industry distribution chart, Labat Africa ranks #67 out of 904 companies in the Drug Manufacturers industry, placing it in the top 7.4%.
Is Labat Africa's 3-Year Revenue Growth Rate too high?
Labat Africa's current 3-Year Revenue Growth Rate is 34.20%. The Drug Manufacturers industry median 3-Year Revenue Growth Rate is 3.70. Labat Africa's value of 34.20% is 824.3% above this industry median. Based on the distribution chart, Labat Africa ranks #67 out of 904 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Labat Africa's 3-Year Revenue Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #67 out of 904 companies for 3-Year Revenue Growth Rate. This places Labat Africa in the top 7% of its industry — outperforming the majority of peers. The industry median 3-Year Revenue Growth Rate is 3.70. Labat Africa's value of 34.20% is 824.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Drug Manufacturers company?
The median 3-Year Revenue Growth Rate among Drug Manufacturers companies is 3.70, based on 904 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current 3-Year Revenue Growth Rate of 34.20% is 824.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Labat Africa and its competitors. For the Drug Manufacturers industry, the median 3-Year Revenue Growth Rate is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current 3-Year Revenue Growth Rate is 34.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.23, compared to a current price of R0.03 — trading 87% below its estimated fair value. The current 3-Year Revenue Growth Rate is 34.20% and 824.3% above the Drug Manufacturers industry median of 3.70. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current 3-Year Revenue Growth Rate is 34.20% as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 
